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Introduction
             The Long QT syndrome (LQTS) can be inherited or acquired and is of particular interest 
and concern at present. Patients with LQTS are predisposed to the ventricular tachyarrhythmia 
torsade de pointes (TdP) which causes syncope and sudden death. Inherited LQTS is the 
prototype of the "primary cardiac arrhythmias" or "cardiac ion channelopathies". The study of 
inherited   LQTS   has   provided   enormous   insight   into   the   molecular   basis   of   cardiac 
electrophysiology and arrhythmogenesis in general. Drug induced LQTS is the most common 
cause of acquired LQTS, and is a pressing public health issue. Considerable attention has been 
focussed on this form of LQTS following the withdrawal from the USA market of a number of 
prescription medications, including terfenedine in 2000 and cisapride in 2001. This review will 
discuss both forms, but with more emphasis on inherited LQTS.                                             
Historical Background Of Inherited  LQTS                                                           
            The first description of inherited LQTS may have been provided by Meissner in Germany 
in 1856. He described a family in which three children experienced sudden sudden death during 
emotional stress. His proband was a deaf female student who died suddenly while being 
reprimanded by the school director. Two siblings had previously died suddenly during emotional 
events. This report antedated the ECG, so there is no knowledge of the QT interval in this family.
            The definitive description of LQTS occurred in 1957. Anton Jervell and Fred Lange-
Nielsen described a Norwegian family in which 4 of 10 children were deaf and had recurrent 
syncope during exercise or emotion.1  Three died suddenly, at ages 4, 5 and 9 years. QT 
prolongation on the ECG was dramatic. Inheritance appeared to be autosomal recessive. A 
similar clinical syndrome of sudden death during exercise and emotion, but with normal hearing 
and autosomal dominant inheritance, was described in 1963 by Romano, et al, and in 1964 by 
Ward.2,3. These two forms of inherited LQTS have respectively become known as the Jervell, 
Lange-Nielsen (J, L-N) and the Romano-Ward (R-W) syndromes.                                   
Prevalence Of Inherited LQTS                                                                                   
            The prevalence of inherited LQTS in the USA is estimated at about 1:7000 persons, 
causing perhaps 2000-3000 sudden deaths in children to young adults each year. The Romano-
Ward variant accounts for over 99% of cases. Jervell, Lange-Nielsen is rare, well less than 1% of 
currently diagnosed cases. LQTS affects all races and ethnic groups, but it is unknown whether 
the prevalence is the same in all groups.                                                                         
Molecular   Genetics                                                                      
            LQTS is caused by mutations of genes which encode for cardiac ion channels. The genes 
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have been numbered in the order of discovery as LQT1, LQT2, etc. Five genes, (LQT1,2,3,5,6) 
with over 200 mutations have thus far been discovered.4 Most families have their "own" novel 
mutation, and there are no real "hot spots", although some exons have a higher number of 
described mutations than others. The gene locus for LQT4 has been mapped to chromosome 4, 
but the gene itself has not yet been identified.5 Table 1 shows the genes, the protein encoded and 
the ion channel involved. Previously other names were used for most genes, and these are shown 
in parentheses. Each of the genes are briefly described, and cartoons of the predicted topology of 
these genes are shown in Figures 1 and 2.
Table 1  Genes causing  Inherited LQTS
KCNQ1 and KCNE1: The products of these two genes coassemble to form the slowly activating 
delayed rectifier potassium channel IKs.6,7 Mutations in either gene reduce the IKs current and 
cause the same LQTS phenotype. KCNQ1 encodes for the larger a subunit and KCNE1 the 
small b subunit of the IKs protein. KCNQ1 consists of 16 exons, spans 400kb, has relatively 
small amino and carboxy termini, and encodes a protein of 676 amino acids8. At least 78, mostly 
missense, mutations have been reported in KCNQ1 primarily occurring in the membrane 
spanning domains and the pore region. KCNE1 has just 3 exons, spanning approximately 40kb 
and encoding a protein of 129 amino acids. It is predicted to have a single transmembrane 
spanning domain with small intra-and extracellular components. Only a few mutations of this 
gene   have   been   identified.                                                          
KCNH2 and KCNE2: Similarly, the gene products of these two genes coassemble to form the 
rapidly activiating delayed rectifier potassium channel IKr.9,10  Mutations in either gene reduce 
the IKr current and cause the same LQTS phenotype. HERG is the "human ether-a-go-go 
related" gene.11 It consists of 16 exons, spans 55kb, and encodes a protein of 1159 amino acids. 
It has a predicted topology similar to KCNQ1, but has more extensive amino and carboxyl 
termini. More than 81 mutations of the gene have been thus far identified.12 Most are in the 
spanning domains and the pore region, but unlike KCNQ1 there are also many mutations in the 
amino and carboxyl termini. KCNE2 is a small protein similar in size and function to KCNE1.13 
It it encodes a protein of 127 amino acids. At least three missense mutations have been 
identified.  SCN5A:  The cardiac Na+ channel gene SCN5A is the LQT3 gene14-16. SCN5A 
appears to encode a complete ion channel (without complexing with a b subunit) with 28 exons 
and 2016 amino acids, spanning 80kb. There are four homologous domains, DI-DIV, each with 
six transmembrane spanning domains, a voltage sensor in the S4 domain, and a pore region 
between the S5 and S6 domains, (Figure 2). At least thirteen mutations of this gene have been 
described, making up approximately 6% of reported LQTS mutations.
Relative frequency of the LQTS genotypes                                                                         
             The   current   data   may   not   be   completely   definitive.   Using   published   genotype 
information, phenotype analysis by ECG findings, and event triggers of patients from centers 
around the world, it appears that about 95% of LQTS cases are caused by mutations of the 
potassium genes. The LQT1/LQT5 combination appears to account for about 60%, LQT2/LQT6 
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about 35%, with mutations of LQT5 and LQT6 alone contributing about 1% each to these 
numbers. The sodium channel gene LQT3 accounts for about 4-5% of the cases, and Jervell, 
Lange-Nielsen less than 1%. The LQT4 genotype is very rare and may be present in only the 
proband   family,   as   no   other   families   with   genotype   have   been   described.  
            Importantly, approximately 30% of phenotypically affected subjects have no mutation 
identified   on  genetic   analysis.   They  may  have   mutations   of   genes   not   yet   recognized. 
Alternatively, they may have mutations of non-coding regions of the known genes, or regulatory 
or modifier genes. Once these families have a genotype found, the genotype distribution may be 
different  than the figures  mentioned  above.                                                             
 
Figure 1.  The predicted topology of the KCNQ1/  KCNH2  genes and the KCNE1/KCNE2 genes, and the 
coassembly into a tetrameric ion channel. Shown in this figure are the KCNQ1 and KCNE1 genes. A similar 
relationship of coassembly of KCNH2 and KCNE2 produces the IKr channel and current.
 
Figure 2. Schematic of the predicted topography of the cardiac Na+ gene SCN5A                            
Clinical   Genetics                                                                    
Romano-Ward: With autosomal dominant transmission, males and females are equally affected. 
Each child of an affected parent has a 50% chance of receiving the abnormal allele. As this is 
just like flipping a coin, in an average sized family all, none or any combination of children may 
have the disorder. Most gene carriers live normal life spans and bear children, so propagation of 
LQTS   is   frequent.                                                                  
Jervell, Lange-Nielsen: Again, with autosomal genes, males and females are equally affected. 
The inheritance of the full syndrome (LQTS plus deafness) is recessive, but with a twist; the 
inheritance of the LQTS portion is dominant, and the hearing loss is recessive.17-21 In a Jervell, 
Lange-Nielsen family, both parents are heterozygous for a mutation of either the KCNQ1 or 
KCNE1 genes. This usually occurs in consanguineous (blood relative) marriage. Each child of 
this marriage has a 25% chance of inheriting the abnormal allele from each parent, thus being 
homozygous or compound heterozygous for LQT1 type mutations. These children have Jervell, 
Lange-Nielsen syndrome, with more severe LQTS than Romano-Ward patients, and profound 
congenital deafness. KCNQ1 is expressed in the inner ear, as well as lung and kidney, in addition 
to the heart.22 At least one normal KCNQ1 allele is necessary for production of the potassium 
rich endolymph in the ear. In the Jervell, Lange-Nielsen children, with no functioning KCNQ1, 
no endolymph is formed, leading to the profound, congenital deafness. Additionally, each child 
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of these parents has a 50% chance of receiving a mutant allele from one or the other parent and 
being heterozygous for LQTS, thus, having Romano-Ward syndrome. The heterozygotes in the 
early reported families had reduced penetrance of the prolonged QT phenotype and symptoms, 
and the diagnosis was missed. QTc averaged about 0.46 seconds. However, the heterozygotes are 
not without risk of cardiac events,23 and all potentially affected family members need to be 
carefully screened by ECG for heterozygous LQTS. The other 25% of offspring of these parents 
get the normal allele from each parent and are normal.                                               
LQTS Phenotype Terminology: As noted above, the 5 genes encode for just 3 ion channels and 
there are really only three phenotypes, LQT1, LQT2 and LQT3. Therefore, to improve 
communication, I will refer to just three phenotypes. In this model, the term LQT1 is used for the 
phenotype of those patients with mutations of the KCNQ1 or KCNE1 genes, as both produce a 
defect in the IKs ion channel and the same phenotype. Similarly for LQT2, caused by mutations 
in either HERG or KCNE2. The LQT3 phenotype is only caused by mutations of the SCN5A 
(LQT3) gene (so far).                                                                                                 
General Clinical Manifestations                                                                                     
            The symptoms of LQTS are syncope and sudden cardiac death. These events are due to 
the ventricular tachyarrhythmia torsade de pointes (TdP), figure 3. Most often, the TdP is self-
terminating, as in figure 3, producing a syncopal episode. In a small minority of events the TdP 
degenerates into ventricular fibrillation and death ensues.
 
Figure 3. Torsade de pointes arrhythmia, showing spontaneous conversion to sinus rhythm with frequent PVCs.
The Patient History:  Syncope, particularly vasovagal syncope, is common in the normal 
population, and occurs at the same rate in LQTS patients. Thus, one cannot just assume that a 
loss of consciousness episode in an LQTS patient is due to the LQTS. The details of the syncope 
history are usually the key to the correct diagnosis. In LQTS it is precipitous and without 
warning in the vast majority of cases. Palpitations and presyncope, either antedating the syncope 
or occurring without syncope, are uncommonly due to LQTS. The reason is that the usual rate of 
TdP is about 300-350/min, and the arrhythmia starts at this rate. No cardiac mechanical function 
occurs at such fast rates, thus, there is nothing to cause palpitations. The immediate cessation of 
cardiac output leads to precipitous syncope. A history of palpitations and presyncope is very 
much more likely to be due to vasovagal physiology, a different cause and type of VT, or SVT. 
As the usual patient considered for LQTS is young, syncope is most commonly vasovagal 
syncope, or not infrequently orthostasis. A very careful history usually clarifies the situation. 
LQTS will be precipitous, as above, no symptoms typical of vasovagal physiology will be 
present, the event will not be during positional change, often absence of respiration and cyanosis 
will be detected, and the duration of the syncope is longer than the usual very brief vasovagal 
event.  
           Further, PVCs are not more common in LQTS patients than the general population, except 
right around the time of episodes of TdP. If PVC's are prominent in a currently asymptomatic 
LQTS patient, they are likely a normal variant or due to something other than LQTS.            
The Family History: A history of unexplained sudden death or repetitive syncope in young 
members of a family is certainly suspicious for LQTS. However, at least one-third24  and 
probably about one-half of gene carriers never have symptoms, and it is not uncommon for 
thefamily history to be negative at the time of diagnosis in a member.                     
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The ECG: The characteristic signs are QT interval prolongation and T wave abnormalities. The 
QT shows reduced penetrance and variable expression, and diagnosis may be difficult by this 
parameter. There is significant variability of the QTc within members of any family, between 
families and to a much lesser extent, between genotypes.                                                       
QT interval: The QTc ranges from about 410 to over 600 msec. The range of values in a normal 
population is about 350 to 460 msec. Consequently, there is overlap of QTc values between 
LQTS and normals in the 410 to 460 msec range. Values in this range are non-diagnostic and 
further studies are required. QTc intervals of  <  440 msec (commonly used as upper 95th 
percentile normal value) on resting ECG are seen in about 12% of gene carriers overall and this 
varies by genotype, see below. Approximately 30% of carriers have a normal to borderline QTc 
410 - 460 msec. About 60% of the normal population has a QTc of 410 - 460 msec, so when 
screening patients for possible LQTS a large percentage will have QTc values which can neither 
make nor exclude the diagnosis of LQTS. Figure 4 shows an ECG from a symptomatic LQT2 
patient with a QTc in this range, emphasizing the complexity of diagnosis by QTc in some 
patients. In this example, the QT is 430 msec, average CL 920 msec, giving a QTc of 448 msec. 
Though subtle, the bifid T waves commonly seen in LQT2 are evident in this ECG.
 
Figure 4. An ECG strip from an LQT2 patient, showing an upper normal QTc at 448 msec.
T wave morphology:  Moss, et al first reported a T wave pattern characteristic for each 
genotype.25 Zhang, et al further described patterns characteristic for each genotype, reporting 
four for LQT1, four for LQT2 and two for LQT3.26  These T patterns can be helpful for 
predicting the correct genotype in families, and can be of assistance in the diagnosis of LQTS in 
cases   of   borderline   QT   duration.                                                                  
Is LQTS the cause of the QT prolongation? It is important to note that there are a number of 
causes of QT prolongation other than inherited LQTS. Included are electrolyte disturbance, use 
of QT prolonging medications, mitral valve prolapse, diabetic autonomic neuropathy and 
cardiomyopathies. These conditions must be excluded when evaluating a patient who has a 
prolonged QT interval before a confident diagnosis of the Long QT syndrome can be made. 
Current evidence suggests that in the absence of these confounding factors, a QTc of > 480 msec 
in females and > 470 msec in males allow the diagnosis of LQTS. QTcs of < 410 msec make 
LQTS quite unlikely. Values between 410 and 460 msec are ambiguous and further testing must 
be performed to clarify the status of these patients. That further testing includes additional ECGs, 
ambulatory ECGs and exercise ECGs. Exercise ECGs seem to be the most definitive. Genetic 
testing is helpful when available, see below.                                                                                 
Clinical Course and Pathophysiology                                                                         
General: Syncope is the predominant symptom, and patients may have one to several hundred 
episodes. One of the most interesting questions is why some patients can have hundreds of 
events and not die, while other patients have sudden death with their first symptom. The 
genotype and mutation type is not the answer, as both situations are seen in members of the same 
family. Symptoms can begin anytime from birth to the fourth decade of life, uncommonly 
thereafter. The peak age of onset and of sudden death is in the preteen to early teenage years in 
LQT1 and the teenage years to early twenties in the LQT2 patients. There are relatively few 
LQT3 patients for analysis, but they seem to have events more in teenage years through the 
thirties. The administration of a QT prolonging medication is commonly the cause of new onset 
syncope   at   ages   over   40.                                                                          
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 2(4): 127-142 (2002)G Michael Vincent, “The Long QT Syndrome”                                                                     132
The LQT1 Phenotype: This is the classic form of LQTS as described in the initial and many 
subsequent publications in the literature. Approximately 60% of LQTS patients have the LQT1 
form. Exercise and emotion are the triggers for over 90% of cardiac events.27 The common 
triggers are running, swimming, startle, anger and fright. LQT1 occurs when a patient has a 
mutation of the KCNQ1 or KCNE1 genes, causing defective IKs channels. The mean QTc in 
LQT1 is 490 msec, with a range from 410 to over 600 msec. Two LQT1 ECGs are shown in 
Figure 5. The left panel shows a near average QTc of 480 msec and the normal T wave pattern. 
The right panel shows the better known broad based T pattern, with a QTc of almost 600 msec. 
These two ECGs show the common LQT1 T morphologies.
                                                  L                                                                                                     R                      
Figure 5. L: 11 year old male LQT1 patient ECG showing a normal T wave pattern and average QTc of about 480 
msec.  R:  A 15  year old  male  with  the broad  based  T  pattern.                                                       
           The IKs channel is responsive to adrenergic stimulation and is the principal current 
responsible for altering action potential duration in response to changes in cycle length. When 
the IKs current is defective, the usual shortening of QT in response to increased heart rate is 
impaired and the QTc progressively lengthens during exercise and early recovery, Figure 6. This 
failure to shorten appropriately during exercise is of considerable diagnostic importance in those 
patients with normal to borderline QTc at baseline. Further, the QTc response varies by 
genotype, and the exercise response helps to identify the genotypes.28
Figure 6. Graph of QTc response during exercise in the three phenotypes.
            The exercise QTc response also provides a rationale for the adrenergic precipitation of 
cardiac events in LQT1 and many LQT2 patients. The mutant channels respond differently to 
adrenergic stimulation than do  the  wild  type  channels,  producing  marked  heterogeneity  of 
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recovery   properties   and   the   substrate   for   the   TdP   arrhythmia   (see   pathophysiology).  
            The degree of channel impairment in LQTS is variable, depending upon the specific 
mutation 10 Most mutations alter channel function by a dominant-negative mechanism in which 
the combination of mutant and wild type units (Figure 4) produces a severe reduction in channel 
current. This is due to a "poison pill" effect, in which the mutant units adversely affect the wild 
type units, causing more dysfunction than would be expected just from the ratio of wild type to 
mutant units. In other mutations, the degree of channel dysfunction is modest, suggesting no 
dominant-negative effect. Thus, there is physiologic heterogeneity of channel function dependent 
upon the specific mutation. Added to this, the channels are not uniformly distributed in the 
myocardium. Further, certain cells, particularly the mid myocardial (M cell) myocytes29, are 
more adversely affected than others, adding to the heterogeneity. The prominent effect on M 
cells predisposes them to development of early afterdepolarizations (EADs) which appear to be 
the   triggering   mechanism   for   the   TdP.                                                        
The LQT2 phenotype: LQT2 is caused by mutations of the HERG or KCNE2 genes. Mutations 
of these genes cause defective IKr channels. The mean QTc in LQT2 patients is 480 msec, with a 
range from 410 to about 600 msec. About 17% of LQT2 patients have a normal QTc (< 440 
msec) on baseline ECG, and about 30% have an interval of < 460 msec. Thus, LQT2 patients are 
more commonly missed on baseline ECG than the other genotypes. The finding of bifid T waves 
in the inferior and lateral leads on the ECG aids in the diagnosis. A typical ECG, showing the 
mean QTc interval and the characteristic bifid T waves is shown in Figure 7.
 
Figure 7. ECG from a 28 year old female with LQT2 and prior symptoms, asymptomatic for a number of years on 
beta blockers. Bifid T waves are evident in leads II, III, AVF and particularly V4.                                           
           The ECG response to exercise in LQT2, figure 6, is heterogeneous. About half of patients 
have worsening of repolarization parameters, i.e., lengthening of the QTc during exercise, like 
the LQT1 patients,. In the others, the QTc has a bimodal character, being long at baseline, 
shortening during exercise and early recovery, and lengthening again in the later recovery, 
Figure 6. LQT2 patients also have more heterogeneity of triggers for their events than does 
LQT1. In approximately 60% of LQT2 patients, the trigger for syncope/cardiac arrest/sudden 
death is adrenergic stimulation, such as exercise and emotion, as in LQT1, consistent with that 
similar proportion having adrenergic worsening of repolarization parameters during exercise. 
The remaining 40% have symptoms during sleep or at rest. Relatively characteristic for LQT2 
are   events   precipitated   by   noises,   such   as   the   telephone,   alarm   clock   and   sirens.30 
            The pathophysiology is similar to LQT1 with prolongation of APD, particularly of the M 
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cells, rendering the cells vulnerable to EADs and the patient to torsade de pointes. Experimental 
studies suggest more heterogeneity of transmural APD in the baseline state than with LQT1, 
perhaps explaining the higher incidence of cardiac events during sleep or at rest in the LQT2 
patients.  
The LQT3 phenotype:  It is estimated that LQT3 accounts for about 4-5 percent of LQTS 
patients. These relatively few patients have been particularly carefully studied and reported, so 
the   emphasis   on   this   genotype   has   been   out   of   proportion   to   the   frequency.   This 
genotype/phenotype is quite interesting in several respects. First, the finding that mutations of 
the cardiac sodium channel gene cause LQTS was somewhat of a surprise since the sodium 
current is a depolarizing current and not a repolarizing current. The mutations cause prolongation 
of the APD by a gain of function abnormality rather than a loss of function as occurs with the 
potassium gene mutations. The mutant channels show impaired inactivation of the channel, 
causing repetitive re-openings throughout the action potential. This persistent inward current 
causes prolongation of the APD, with particular prolongation in M cells, as opposed to epi- and 
endocardial cells.31-33 A unique feature of the LQT3 phenotype is that about 90% of cardiac 
events occur during sleep.27 Also they generally occur at later ages than in LQT1 and LQT2. 
Further, the ECG phenotype is rather different as well. The characteristic ECG pattern is shown 
in Figure 8. Note the long ST segment and unusual T wave morphology, which are characteristic 
for this genotype, but about one-third of LQT3 gene carriers have more normal ST duration and 
T waves. Note the worsening on repolarization after the long cycle length. This common 
observation may provide insight into the sudden death during sleep, as enhanced post pause, or 
bradycardia induced, repolarization disturbance may trigger TdP. 
 
Figure 8. A two-lead rhythm strip showing the typical LQT3 pattern, with long ST segment and abnormal T waves.
            The mean QTc in LQT3 is less certain than in LQT1 or 2 due to the smaller number of 
subjects who have been studied, but appears to be longer at about 510 to 520 msec. Families with 
much shorter QTcs have been reported, however, raising the possibility that when a larger 
number of LQT3 families are reported, the mean QTc may be similar to LQT1 and LQT2. 
LQT4: This locus was identified by linkage analysis in one French family 5, but even now, a 
number of years later, the gene has not yet been reported. It is probable that this is a very rare 
genotype, and may be only in this single family. The phenotype in LQT4 is unique among the 
LQTS genotypes, with a high incidence of atrial fibrillation and unusual T wave morphology.
Diagnosis
            The diagnosis is based primarily on QT prolongation on the ECG. A point scoring system 
of ECG and symptom and family history criteria has been proposed and often used, though it has 
never been validated as to sensitivity and specificity.34  Current data suggests a confidant 
diagnosis of LQTS can be made with a QTc of > 470 msec in males and > 480 msec in females 
in the absence of drugs, cardiac disease, or other diseases/factors which could independently 
lengthen the QT interval. Conversely, LQTS is very unlikely with a QTc < 400 msec. QTcs 
between 410 and 460 msec are indeterminant and these patients require further investigation. 
Additional ECGs, exercise ECGs (see above) and ambulatory ECGs are often very helpful. 
Ambulatory ECGs require a different QTc cutpoint than diagnostic ECG recordings. Available 
literature indicates normals may have QTc values up to 500 msec on a common basis, so I use > 
500 msec as suggesting LQTS.  Diagnosis  is  helped  considerably by  the  presence  of  LQTS 
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characteristic T wave morphology, at rest, or occurring during exercise or ambulatory ECG. 
Syncope with characteristics typical for LQTS events also adds considerably to the diagnostic 
certainty, and identification of TdP arrhythmia seems essentially pathognomonic for a QT 
prolongation syndrome. LQTS in other family members raises the probability that a given patient 
has LQTS. Cardiac cath and EP studies are not very helpful, and rarely used for diagnostic 
inquiry   into   LQTS.                                                                                          
    Commercial genetic testing for de novo mutations is restricted to selected, higher probability, 
exons, as done by, for example, GeneDx. The sensitivity/specificity of this screening strategy is 
not well defined. Commercial genetic testing for members of families with a known mutation is 
available, with analysis limited to the exon involved. De novo mutation screening is available in 
some   research   laboratories.                                                                      
Risk   of   syncope   and   sudden   death                                                            
            The early publications emphasized a high risk of serious events. These cases were, of 
course, the most obvious and severe, the typical "tip of the ice-berg" problem. As the much 
larger number of less symptomatic and asymptomatic patients were detected (the base of the 
iceberg), particularly after genetic testing became available, it became evident that the risk was 
much lower than previously reported. The earliest clear evidence of this came from the first 
genotype-phenotype study.24 In this report it was found that one-third of gene carriers (identified 
by linkage analysis in the first genetic study)35, many middle age to older, had never had 
symptoms. Further, it was determined that the sudden death rate in gene carriers or obligate 
carriers was 9% over 40 years. This put a completely different perspective on sudden death risk 
in LQTS than had previously existed.                                                                     
            The most current and definitive data come from the International LQTS registry. Zareba, 
et al36 reported on LQTS patients of all three genotypes. The death rate over 40 years was about 
4% for each genotype. This finding has tremendous importance for treatment and follow-up 
strategies in LQTS patients. The rather low incidence of sudden death indicates that we badly 
need to identify reliable risk markers, not accurately possible at present. With such data, the large 
majority, who are at low risk, might be stratified to no treatment, whereas those at higher risk 
could be appropriately managed with aggressive and target driven beta-blocker therapy, ICDs or 
other genetic based therapies as they become available. Also, the Registry study determined that 
the frequency of cardiac events (syncope, aborted cardiac arrest and sudden death) was highest in 
LQT1 (60% of patients), then LQT2 (40%) and lowest in LQT3 (18%). Since the rate of death 
was the same in each genotype, the percentage of events which were lethal was highest in the 
LQT3   patients.                                                                                    
Therapy
Beta-blockers:  In the initial publication by Jervell and Lange-Nielsen the exercise/emotion 
induction of events was clear and well described. Increased QT prolongation was evident during 
exercise and with epinephrine administration. Thus, the adverse influence of adrenergic tone was 
integral to the description of the disease and this has been confirmed in many subsequent 
publications. This led to the use of Propranolol around 1959 as an investigational agent. 
Subsequently, beta-blockers have been the mainstay of therapy over many years. A number of 
publications regarding treatment have appeared in the last few years37-40, but this is a very 
dynamic and changing area and many questions exist. Regarding beta-blockers, the long term 
empiric observations and recent studies41  have shown a high degree, but not complete, 
effectiveness of beta-blockers. They appear to be very effective in the classic LQTS patient with 
LQT142 effective but perhaps somewhat less in LQT2, and possibly least effective in LQT3. 
Many, but not all, of the failures of beta-blocker medication have been due to omission of one or 
usually more doses of the medication, or the administration of a QT prolonging drug by an 
uninformed physician or an over the counter drug use by the patient. In some other failures, the 
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dose has probably been insufficient. Clearly, careful discussion with the patient about the need to 
take the agent daily is important, just as with all other serious and potentially life threatening 
conditions.  
Prophylaxis: It is important to note that sudden death may be the first manifestation of the 
disease. Consequently, all asymptomatic LQT1 and LQT2 patients, particularly children, should 
be treated prophylactically with beta-blockers, as one cannot accurately predict the risk in a 
given patient and a "second chance" may not be available. Because the risk of events and death 
decrease over time, it may be unnecessary to treat a patient who is over 40 years or so and life-
long asymptomatic at the time of diagnosis. Data are at present insufficient to clearly propose a 
treatment strategy for asymptomatic LQT3 patients. Laboratory data suggest beta-blockers might 
be adverse, but clinical data is not available to confirm nor deny this observation. Since only 
about 4% of LQT3 patients seem to die, it is difficult to recommend an ICD for the 
asymptomatic patients, but data are lacking as to the best course.                           
Pacemakers:  Pacemakers   play   a   role   in   some   patients,   particularly   those   with   marked 
bradycardia or pauses, and those who can't tolerate beta-blockers. 43-45                           
ICDs: Implantable cardiac defibrillators are being placed in a number of patients at the present 
time. Data supporting their common use are not available. Based on the relative infrequency of 
death as noted above, the demonstrated benefit of beta-blockers, and the frequency with which 
gene carriers never have symptoms, there seems no reason to place a prophylactic ICD in an life-
long asymptomatic patient nor one with a few syncopal episodes a number of years previously. 
Exceptions to this rule are Jervell, Lange-Nielsen patients, who clearly have a much higher risk 
of sudden death, especially in early childhood, and patients with LQTS associated with 
syndactyly who also have similar risks.46-48 Clear indications for an ICD include patients with 
syncope or aborted cardiac arrest on appropriate doses of beta-blockers. A probable indication is 
a history of cardiac arrest off beta-blockers, though data on persistent risk of a repeat event are 
limited and variable, and probably need to be considered by genotype.                                   
Investigational   therapies                                                                                    
LQT2: The paradoxical finding that increased extracellular potassium concentration improved 
IKr channel function11 led to the idea that high dose potassium administration coupled with 
spironolactone to decrease excretion might be of benefit to LQT2 patients. A pilot trial in a small 
number of LQT2 patients showed shortening of QT duration and normalization of T wave 
morphology49 and evidence that benefit continued over a few years.50 Other investigators found 
limited long term ECG effectiveness and difficulty maintaining the serum potassium at desired 
levels.51  It is not known whether potassium administration has any effect, beneficial or 
otherwise, on symptoms and risk of sudden death. A clinical trial is ongoing but it may be some 
time   before   this   question   is   answered.                                                            
LQT3: The early finding of repetitive openings of the sodium channel as the mechanism of APD 
and QT prolongation in LQT3 patients suggested that a sodium channel blocker may be of 
benefit in these patients. Preliminary studies showed improvement in ECG parameters.52-56 It is 
not known if such treatment will reduce syncope and sudden death risk. Ongoing clinical trials 
are   being   performed.                                                                          
Acquired LQTS: Acquired LQTS is much more frequent than the inherited form, but accurate 
estimates of the frequency are unavailable. The most common cause is medication induced. 
Perhaps the initial recognition of this problem was the description of "quinidine syncope and 
sudden death".57 Since then, many medications, and also illicit drugs, have been demonstrated to 
have this adverse property. A number of medications have been withdrawn from the market, 
most notably perhaps terfenedine in 2000 and cisapride in 2001, amongst a lot of publicity and 
concern by physicians and medical organizations, the pharmaceutical industry, the FDA, and the 
legal   profession.   Currently,   more   than   50   commonly   prescribed   medications   cause   QT 
prolongation and/or have been associated with torsade de pointe or sudden death. In order to help 
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physicians and other providers, as well as patients, know which drugs have this effect, they can 
be viewed on the web at www.qtdrugs.com  and www.sads.org.  The risk of acquired LQTS 
from these medications varies widely, ranging from well less than 1% of patients to whom the 
medication is given, to over 10%. While, on average, the risk is very low, some of the drugs are 
prescribed for many millions of patients each year. Consequently, the cumulative risk can be 
high enough to pose a substantial public health risk, e.g. terfenedine and cisapride. The 
mechanism of effect is block of the IKr current. 9,58-60. Drug induced LQTS has been long been 
considered an idiosyncratic response, but the recent molecular findings have shed light on 
potential predisposing conditions.61 In most current cases, the mechanism rendering one patient 
vulnerable to torsade upon administration of the drug, but not most persons exposed to the drug, 
remains unknown. The recognition that both drug induced and the LQT2 form of congenital 
LQTS affect the IKr channel has suggested that some patients who have drug induced LQTS 
may have a predisposing forme fruste of congenital LQTS, the hypothesis being that their 
underlying defect makes them susceptible to TdP when repolarization is further impaired by 
administration of drugs which decrease potassium channel function. 62- 65                                            
             Prevention of drug induced LQTS certainly includes better methods for educating 
physicians and the public. Many events have occurred when patients are given a second QT 
prolonging drug, or a drug which blocks the metabolism of an existing QT prolonging drug. 
Computerized pharmacy records for each patient, with drug-drug interaction alerts, will allow 
pharmacists to screen new prescriptions for patients for this adverse possibility. Physicians can 
inform patients of potential side effects when prescribing QT prolonging agents, so at least the 
patients will seek medical attention if adverse symptoms occur. Further, there are certain 
portions of the population who are at greater risk than others. Female gender conveys a 
substantially increased risk for drug induced LQTS,66and QT prolonging drugs should be used 
with caution. The senior population, with reduced renal and hepatic function, eliminate QT 
prolonging drugs more slowly and are at increased risk for higher serum levels. They often have 
multiple prescriptions and are further at risk for drug-drug interactions or altered metabolism. A 
disproportionate percentage of QT prolonging drugs are in the psychiatric arena, and patients 
with psychiatric needs are at increased risk of receiving such a drug, plus, may be more at risk 
for mistakes and errors in their use and administration. In the future, it may be easy to determine 
early in the course of drug development which compounds will have QT prolongation 
effect,67thus preventing agents with this effect from reaching the market.                       
             Acquired LQTS also occurs as a consequence of a number of acute and chronic 
neurologic disorders, such as subarachnoid hemorrhage and diabetic autonomic neuropathy 68-70, 
presumably due to effects of these diseases on the autonomic nervous system center71, 72. An 
association between Long QT intervals and sudden infant death syndrome (SIDS) has also been 
reported73. Some of these cases probably have inherited LQTS. Others may be due to the 
immature autonomic nervous system of infants, with QT prolongation, but with death due to 
respiratory difficulties from the immature autonomic system. As is well known, electrolyte 
disturbances such as hypokalemia and hypomagnesemia also cause QT prolongation, T wave 
abnormalities,  and  arrhythmias.                                                                               
Diagnosis and treatment: QT prolongation >460 msec, a increment in QT duration of 30 msec 
from baseline, and torsade de pointes arrhytmia are the findings. The degree of prolongation 
which places patients at high risk is not well defined. A QTc of 500 msec or greater has been 
suggested as cause for concern, but it is likely that some patients are at risk at shorter intervals, 
just as in inherited LQTS. Cessation of the drug is the primary treatment. Recognition of patients 
at risk is important. Physicians might consider obtaining an ECG within a few days of 
administration of a QT prolonging drug, assessing for prolongation, and should consider 
stopping the drug if QT prolongation is identified. An ECG should be obtained any time a patient 
on one of the medications experiences palpitations, presyncope or syncope. The medication must 
be stopped upon recognition of TdP. Physicians should weigh the risk of a QT prolonging drug 
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with the expected benefit and only prescribe the drug when alternatives are not available or not 
nearly   as   effective   as   the   QT   prolonging   drug.                                                  
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